RemeGen Co (FRA:REG) Other Financing: €-13.2 Mil (TTM As of Dec. 2025)


FRA:REG RemeGen Co Ltd FRA:REG
39 GF Score
Price €9.36
GF Value €15.26
Valuation Possible Value Trap
! 6 Warning Signs
View Full Analysis

What is RemeGen Co Other Financing?

RemeGen Co FRA:REG -2.42% 39 Other Financing is €-13.2 Mil as of Dec. 2025. GuruFocus rates FRA:REG with a GF Score™ of 39/100 and a GF Value™ of €15.26 (Possible Value Trap). The stock has 6 warning signs investors should review.

RemeGen Co's Other Financing for the three months ended in Dec. 2025 was €-8.4 Mil.

RemeGen Co's Other Financing for the trailing twelve months (TTM) ended in Dec. 2025 was €-13.2 Mil.

RemeGen Co Other Financing Historical Data

* Premium members only.

The historical data trend for RemeGen Co's Other Financing can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

RemeGen Co Other Financing Chart

RemeGen Co Annual Data
Trend Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Other Financing
Get a 7-Day Free Trial -2.77 -13.45 -2.98 -10.05 -15.00

RemeGen Co Quarterly Data
Dec18 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Jun25 Sep25 Dec25
Other Financing Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -6.04 -1.86 0.00 -4.77 -8.41
FRA:REG
39GF Score
RemeGen Co Ltd FRA:REG
Other Financing is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

RemeGen Co Other Financing Calculation

Other Financing represents other cash flow from financing activity that not otherwise classified, which includes:
Proceeds From Stock Option Exercised
Other Financing Charges

Other Financing for the trailing twelve months (TTM) ended in Dec. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was €-13.2 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Other Financing →
What does a Other Financing of €-13.2 Mil mean?
RemeGen Co (FRA:REG) has a Other Financing of €-13.2 Mil as of Dec. 2025. Other Financing represents other cash flow from financing activity that not otherwise classified. View historical data for RemeGen Co and its competitors.
Is RemeGen Co's Other Financing too high?
RemeGen Co's current Other Financing is €-13.2 Mil. Overall, RemeGen Co has a GF Score™ of 39/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does RemeGen Co's Other Financing compare to VRTX and REGN?
RemeGen Co's Other Financing of €-13.2 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Other Financing for a Biotechnology company?
A good Other Financing depends on the Biotechnology industry context. However, Other Financing should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Other Financing mean?
A high Other Financing can signal that a stock is expensive relative to its fundamentals. Other Financing represents other cash flow from financing activity that not otherwise classified. View historical data for RemeGen Co and its competitors. RemeGen Co's current Other Financing is €-13.2 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is RemeGen Co stock overvalued right now?
Based on GuruFocus' analysis, RemeGen Co (FRA:REG) is currently considered Possible Value Trap. The stock's GF Value™ is €15.26, compared to a current price of €9.36 — trading 38.7% below its estimated fair value. The current Other Financing is €-13.2 Mil. RemeGen Co's overall GF Score™ is 39/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Other Financing calculated?
Other Financing is calculated from a company's financial statements. For RemeGen Co (FRA:REG), the current Other Financing is €-13.2 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is RemeGen Co (FRA:REG) Overvalued in 2026?

Based on GuruFocus' analysis, RemeGen Co stock appears to be undervalued. The current stock price of €9.36 is trading 38.7% below its estimated GF Value™ of €15.26. GuruFocus considers RemeGen Co to be Possible Value Trap.

Key valuation signals for FRA:REG:

  • Other Financing: €-13.2 Mil
  • GF Value™: €15.26 vs. price of €9.36 (38.7% below fair value)
  • GF Score™: 39/100 with 6 warning signs

No single metric tells the full story. See the FRA:REG stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

RemeGen Co Business Description

Address 58 Middle Beijing Road, Yantai Area of Shandong Pilot Free Trade Zone, Yantai Development Zone, Yantai, CHN
RemeGen Co Ltd is a China-based company mainly engaged in the research, development and manufacture of biopharmaceuticals. The company offers Telitacicept (RC18) for use in the treatment of systemic lupus erythematosus an autoimmune disease and Disitamab Vedotin (RC48) for use in the treatment of various cancers. The company's products are mainly used to treat severe diseases such as autoimmune diseases, oncology, and ophthalmology. It has its operations in China and the USA and derives the majority of its revenue from China.
39GF Score

Get the complete analysis for FRA:REG

Other Financing is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€9.36
Price
€15.26
GF Value